SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
谷小直
Lv1
80 积分
2023-08-28 加入
最近求助
最近应助
互助留言
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
12天前
已完结
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial
1个月前
已关闭
139P HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
1个月前
已完结
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
2个月前
已关闭
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
2个月前
已关闭
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2个月前
已完结
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
3个月前
已完结
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
3个月前
已完结
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
3个月前
已完结
Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
4个月前
已关闭
没有进行任何应助
有文章了【积分已退回】
2个月前
没有人答应【积分已退回】
2个月前
无人回复【积分已退回】
4个月前
重新发求助【积分已退回】
4个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论